Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Dec;38(12):2717–2721. doi: 10.1128/aac.38.12.2717

Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.

L E Bermudez 1, C B Inderlied 1, P Kolonoski 1, M Petrofsky 1, L S Young 1
PMCID: PMC188275  PMID: 7695252

Abstract

Bacteremic infection caused by organisms of the Mycobacterium avium complex (MAC) is common in patients with AIDS. We evaluated both clarithromycin and dapsone alone and in combination for the treatment and prevention of disseminated MAC disease in beige mice. In the therapeutic model, C57BL/6 beige mice were infected intravenously with strain 101 of MAC (serovar 1). After 1 week postinfection, mice were given clarithromycin (200 mg/kg of body weight per day) and dapsone (15 mg/kg of body weight per day) alone or in combination by gavage. Treatment with clarithromycin resulted in a significant reduction in bacteremia and the numbers of CFU of MAC in the liver and spleen. Treatment with dapsone had no effect on the mycobacterial counts in blood, liver, or spleen, and the combination of dapsone with clarithromycin was no better than clarithromycin as a single agent. Clarithromycin and dapsone were used to prevent systemic disease in beige mice infected orally with MAC 101. Clarithromycin prophylaxis was associated with a significant reduction in the numbers of bacteria in the liver, spleen, and appendix compared with those in controls. Prophylaxis with dapsone resulted in a mild reduction in the numbers of MAC in the spleen but not in the other tissues. Clarithromycin both treats and prevents MAC disease in beige mice. Dapsone has no therapeutic effect, but it does have a slight prophylactic effect, and in combination with clarithromycin it does not abrogate the effect of clarithromycin.

Full text

PDF
2717

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bermudez L. E., Petrofsky M., Kolonoski P., Young L. S. An animal model of Mycobacterium avium complex disseminated infection after colonization of the intestinal tract. J Infect Dis. 1992 Jan;165(1):75–79. doi: 10.1093/infdis/165.1.75. [DOI] [PubMed] [Google Scholar]
  2. Bermudez L. E., Young L. S., Inderlied C. B. Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells. Antimicrob Agents Chemother. 1994 May;38(5):1200–1202. doi: 10.1128/aac.38.5.1200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bertram M. A., Inderlied C. B., Yadegar S., Kolanoski P., Yamada J. K., Young L. S. Confirmation of the beige mouse model for study of disseminated infection with Mycobacterium avium complex. J Infect Dis. 1986 Jul;154(1):194–195. doi: 10.1093/infdis/154.1.194. [DOI] [PubMed] [Google Scholar]
  4. Blum R. N., Miller L. A., Gaggini L. C., Cohn D. L. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr. 1992;5(4):341–347. [PubMed] [Google Scholar]
  5. Damsker B., Bottone E. J. Mycobacterium avium-Mycobacterium intracellulare from the intestinal tracts of patients with the acquired immunodeficiency syndrome: concepts regarding acquisition and pathogenesis. J Infect Dis. 1985 Jan;151(1):179–181. doi: 10.1093/infdis/151.1.179. [DOI] [PubMed] [Google Scholar]
  6. Dautzenberg B. Clinical trials in Mycobacterium avium therapy: lessons to take home. Res Microbiol. 1994 Mar-Apr;145(3):197–206. doi: 10.1016/0923-2508(94)90018-3. [DOI] [PubMed] [Google Scholar]
  7. Dautzenberg B., Saint Marc T., Meyohas M. C., Eliaszewitch M., Haniez F., Rogues A. M., De Wit S., Cotte L., Chauvin J. P., Grosset J. Clarithromycin and other antimicrobial agents in the treatment of disseminated Mycobacterium avium infections in patients with acquired immunodeficiency syndrome. Arch Intern Med. 1993 Feb 8;153(3):368–372. [PubMed] [Google Scholar]
  8. Dautzenberg B., Truffot C., Legris S., Meyohas M. C., Berlie H. C., Mercat A., Chevret S., Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):564–569. doi: 10.1164/ajrccm/144.3_Pt_1.564. [DOI] [PubMed] [Google Scholar]
  9. Fernandes P. B., Hardy D. J., McDaniel D., Hanson C. W., Swanson R. N. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother. 1989 Sep;33(9):1531–1534. doi: 10.1128/aac.33.9.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Furney S. K., Roberts A. D., Orme I. M. Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice. Antimicrob Agents Chemother. 1990 Sep;34(9):1629–1632. doi: 10.1128/aac.34.9.1629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Gangadharam P. R., Perumal V. K., Jairam B. T., Rao P. N., Nguyen A. K., Farhi D. C., Iseman M. D. Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am Rev Respir Dis. 1987 Aug;136(2):329–333. doi: 10.1164/ajrccm/136.2.329. [DOI] [PubMed] [Google Scholar]
  12. Gelber R. H. Progress in the chemotherapy of leprosy: status, issues and prospects. Prog Drug Res. 1990;34:421–445. doi: 10.1007/978-3-0348-7128-0_14. [DOI] [PubMed] [Google Scholar]
  13. Gonzalez A. H., Berlin O. G., Bruckner D. A. In-vitro activity of dapsone and two potentiators against Mycobacterium avium complex. J Antimicrob Chemother. 1989 Jul;24(1):19–22. doi: 10.1093/jac/24.1.19. [DOI] [PubMed] [Google Scholar]
  14. Hawkins C. C., Gold J. W., Whimbey E., Kiehn T. E., Brannon P., Cammarata R., Brown A. E., Armstrong D. Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1986 Aug;105(2):184–188. doi: 10.7326/0003-4819-105-2-184. [DOI] [PubMed] [Google Scholar]
  15. Heifets L. B., Lindholm-Levy P. J., Comstock R. D. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):856–858. doi: 10.1164/ajrccm/145.4_Pt_1.856. [DOI] [PubMed] [Google Scholar]
  16. Heifets L., Mor N., Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother. 1993 Nov;37(11):2364–2370. doi: 10.1128/aac.37.11.2364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Horsburgh C. R., Jr Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med. 1991 May 9;324(19):1332–1338. doi: 10.1056/NEJM199105093241906. [DOI] [PubMed] [Google Scholar]
  18. Hughes W. T., Kennedy W., Dugdale M., Land M. A., Stein D. S., Weems J. J., Jr, Palte S., Lancaster D., Gidan-Kovnar S., Morrison R. E. Prevention of Pneumocystis carinii pneumonitis in AIDS patients with weekly dapsone. Lancet. 1990 Oct 27;336(8722):1066–1066. doi: 10.1016/0140-6736(90)92533-n. [DOI] [PubMed] [Google Scholar]
  19. Inderlied C. B., Kolonoski P. T., Wu M., Young L. S. In vitro and in vivo activity of azithromycin (CP 62,993) against the Mycobacterium avium complex. J Infect Dis. 1989 May;159(5):994–997. doi: 10.1093/infdis/159.5.994. [DOI] [PubMed] [Google Scholar]
  20. Kemper C. A., Meng T. C., Nussbaum J., Chiu J., Feigal D. F., Bartok A. E., Leedom J. M., Tilles J. G., Deresinski S. C., McCutchan J. A. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. Ann Intern Med. 1992 Mar 15;116(6):466–472. doi: 10.7326/0003-4819-116-6-466. [DOI] [PubMed] [Google Scholar]
  21. Klemens S. P., DeStefano M. S., Cynamon M. H. Activity of clarithromycin against Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother. 1992 Nov;36(11):2413–2417. doi: 10.1128/aac.36.11.2413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Perronne C., Gikas A., Truffot-Pernot C., Grosset J., Pocidalo J. J., Vilde J. L. Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother. 1990 Aug;34(8):1508–1511. doi: 10.1128/aac.34.8.1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rastogi N., Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother. 1991 Mar;35(3):462–470. doi: 10.1128/aac.35.3.462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Truffot-Pernot C., Ji B., Grosset J. Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex. Antimicrob Agents Chemother. 1991 Aug;35(8):1677–1678. doi: 10.1128/aac.35.8.1677. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Young L. S. Mycobacterium avium complex infection. J Infect Dis. 1988 May;157(5):863–867. doi: 10.1093/infdis/157.5.863. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES